Matteo Landriscina
Overview
Explore the profile of Matteo Landriscina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soccio P, Moriondo G, Scioscia G, Tondo P, Bruno G, Giordano G, et al.
Noncoding RNA Res
. 2024 Dec;
10:261.
PMID: 39737057
[This corrects the article DOI: 10.1016/j.ncrna.2024.09.008.].
2.
Fedele P, Landriscina M, Moraca L, Gadaleta-Caldarola A, Cusmai A, Giuliani F, et al.
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685899
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the standard of care for hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer in combination with endocrine therapy....
3.
Garofoli M, Maiorano B, Bruno G, Giordano G, Falagario U, Necchi A, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39627072
Background And Objective: Circulating tumor DNA (ctDNA) testing provides valuable prognostic and predictive information for guiding therapeutic choices and monitoring disease progression and drug resistance for urological tumors. Our review...
4.
Fedele P, Landriscina M, Moraca L, Cusmai A, Gnoni A, Licchetta A, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456537
Background: Metastatic HR+/HER2- breast cancer is commonly treated with CDK4/6 inhibitors in combination with endocrine therapy. However, the efficacy and safety of this approach in elderly patients (≥70 years) remain...
5.
Prinzi F, Salani F, Rimini M, Rizzato M, Antonuzzo L, Camera S, et al.
Oncologist
. 2024 Oct;
PMID: 39427227
Background: In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our...
6.
Soccio P, Moriondo G, Scioscia G, Tondo P, Bruno G, Giordano G, et al.
Noncoding RNA Res
. 2024 Sep;
10:91-97.
PMID: 39315340
Introduction: The relationship between obstructive sleep apnea (OSA) and cancer has been recognized for some time now. However, little is known about the mechanisms by which sleep apnea promotes tumorigenesis...
7.
Bruno G, Pietrafesa M, Crispo F, Piscazzi A, Maddalena F, Giordano G, et al.
J Mol Med (Berl)
. 2024 Aug;
102(10):1285-1296.
PMID: 39210159
Metabolic rewiring promotes cancer cell adaptation to a hostile microenvironment, representing a hallmark of cancer. This process involves mitochondrial function and is mechanistically linked to the balance between mitochondrial biogenesis...
8.
Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, et al.
Clin Genitourin Cancer
. 2024 Jul;
22(5):102147.
PMID: 39030142
Introduction: The administration of proton pump inhibitors (PPIs) is a common practice to reduce gastro-esophageal adverse events associated with drug treatments but may impair absorption and exposure to oncology drugs....
9.
Orsi G, Carconi C, Ghiorzo P, Carrera P, Pastorino L, Presi S, et al.
Eur J Cancer
. 2024 Jul;
208:114226.
PMID: 39029294
Background And Aim: Germline BRCA1-2 test is routinely recommended in Pancreatic Cancer (PC) patients, due to its clinical-epidemiological relevance. Data on the prevalence of germline pathogenic variants (gPV) in other...
10.
Rimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, et al.
Eur J Cancer
. 2024 Jul;
208:114199.
PMID: 39002348
Background: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy...